[Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections].
Ofloxacin was used in the treatment of 24 patients with chronic bronchitis or pneumonia at the background of chronic bronchopulmonary and cardiovascular diseases. The drug was administered in accordance with 2 regimens: orally in a dose of 400 mg once a day (group I) and intravenously in a dose of 200 mg twice a day for 2 to 4 days followed by the drug oral use in the same dosage for 6 to 8 days (group II). The trial included comparison of the treatment efficacy by a complex of clinicobacteriological indices, estimation of the drug pharmacokinetics under the two regimens and prediction of the drug concentrations in blood with the mathematical models. High clinical and bacteriological efficacies of ofloxacin were shown under both the regimens. The pathogen eradication under both the regimens was observed in 61.5 and 72.7 per cent of the cases in groups I and II respectively. Dependence of the ofloxacin blood concentrations in the patients on the dosage regimen was detected. The pharmacokinetic studies demonstrated the possible prediction of the drug blood concentrations after the multiple administrations based on the calculated parameters.
Belousov
O B
OB
Gutkin
A B
AB
Sokolov
A V
AV
Tishchenkova
I F
IF
Efremenkova
O V
OV
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism; D004334:Drug Administration Schedule; D006801:Humans; D007275:Injections, Intravenous; D008433:Mathematics; D008875:Middle Aged; D008954:Models, Biological; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011379:Prognosis; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000890:Anti-Infective Agents; D015242:Ofloxacin